Tempest Therapeutics Analyst Ratings
Tempest Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 5637.7% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 06/05/2023 | 5637.7% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 05/30/2023 | 5637.7% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 05/11/2023 | 5637.7% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 04/28/2023 | 2195.08% | Ladenburg Thalmann | $8 → $14 | Maintains | Buy |
| 03/23/2023 | 883.61% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 03/23/2023 | 5637.7% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 02/08/2023 | 5637.7% | HC Wainwright & Co. | → $35 | Maintains | Buy |
| 09/15/2022 | 1211.48% | Ladenburg Thalmann | → $8 | Initiates Coverage On | → Buy |
| 05/16/2022 | 5637.7% | HC Wainwright & Co. | $51 → $35 | Maintains | Buy |
| 10/21/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/13/2021 | 8260.66% | HC Wainwright & Co. | → $51 | Initiates Coverage On | → Buy |
| 07/06/2021 | 3670.49% | Piper Sandler | → $23 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/11/2023 | 5637.7% | HC Wainwright & Co. | → 35 美元 | 重申 | 購買 → 購買 |
| 06/05/2023 | 5637.7% | HC Wainwright & Co. | → 35 美元 | 重申 | 購買 → 購買 |
| 05/30/2023 | 5637.7% | HC Wainwright & Co. | → 35 美元 | 重申 | 購買 → 購買 |
| 05/11/2023 | 5637.7% | HC Wainwright & Co. | → 35 美元 | 重申 | 購買 → 購買 |
| 04/28/2023 | 2195.08% | 拉登堡塔爾曼 | 8 美元 → 14 美元 | 維護 | 購買 |
| 03/23/2023 | 883.61% | 派珀·桑德勒 | 10 美元 → 6 美元 | 維護 | 超重 |
| 03/23/2023 | 5637.7% | HC Wainwright & Co. | → 35 美元 | 重申 | → 購買 |
| 02/08/2023 | 5637.7% | HC Wainwright & Co. | → 35 美元 | 維護 | 購買 |
| 2022 年 9 月 15 日 | 1211.48% | 拉登堡塔爾曼 | → 8 美元 | 啓動覆蓋開啓 | → 購買 |
| 05/16/2022 | 5637.7% | HC Wainwright & Co. | 51 美元 → 35 美元 | 維護 | 購買 |
| 2021 年 10 月 21 日 | — | 威廉布萊爾 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 2021 年 7 月 13 日 | 8260.66% | HC Wainwright & Co. | → 51 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 6 月 7 日 | 3670.49% | 派珀·桑德勒 | → 23 美元 | 啓動覆蓋開啓 | → 超重 |
What is the target price for Tempest Therapeutics (TPST)?
Tempest Therapeutics（TPST）的目標價格是多少？
The latest price target for Tempest Therapeutics (NASDAQ: TPST) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $35.00 expecting TPST to rise to within 12 months (a possible 5637.70% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月11日公佈了Tempest Therapeutics（納斯達克股票代碼：TPST）的最新目標股價。這家分析公司將目標股價定爲35.00美元，預計TPST將在12個月內升至5637.70％（可能上漲5637.70％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Tempest Therapeutics (TPST)?
分析師對Tempest Therapeutics（TPST）的最新評級是多少？
The latest analyst rating for Tempest Therapeutics (NASDAQ: TPST) was provided by HC Wainwright & Co., and Tempest Therapeutics reiterated their buy rating.
Tempest Therapeutics（納斯達克股票代碼：TPST）的最新分析師評級由HC Wainwright & Co. 提供，Tempest Therapeutics重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Tempest Therapeutics (TPST)?
Tempest Therapeutics（TPST）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tempest Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tempest Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Tempest Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Tempest Therapeutics的最後一次評級是在2023年8月11日提交的，因此你應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Tempest Therapeutics (TPST) correct?
分析師對 Tempest Therapeutics (TPST) 的評級正確嗎？
While ratings are subjective and will change, the latest Tempest Therapeutics (TPST) rating was a reiterated with a price target of $0.00 to $35.00. The current price Tempest Therapeutics (TPST) is trading at is $0.61, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Tempest Therapeutics（TPST）評級得到了重申，目標股價爲0.00美元至35.00美元。Tempest Therapeutics（TPST）目前的交易價格爲0.61美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。